trending Market Intelligence /marketintelligence/en/news-insights/trending/x9061erxbz_z5ft80cnosw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Soligenix, IDT Biologika extend collaboration for biodefense vaccine

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Soligenix, IDT Biologika extend collaboration for biodefense vaccine

Soligenix Inc. extended its collaboration with IDT Biologika for the manufacture of RiVax, Soligenix's proprietary recombinant subunit vaccine developed to protect against exposure to ricin toxin.

Soligenix will advance the formulation and filling processes and will continue development and validation of analytical methods established at IDT to move the program toward a commercially viable scalable technology for the RiVax vaccine.

Soligenix has been developing RiVax, in conjunction with its heat stabilization technology, ThermoVax, as a heat-stable biodefense vaccine. The RiVax project is supported with National Institute of Allergy and Infectious Diseases funding of up to $24.7 million.